


PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6183767

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| BAYER PHARMA AKTIENGESELLSCHAFT | 02/04/2020 |
| RECEIVING PARTY DATA | |
| Name: | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS |
| Street Address: | IM NEUENHEIMER FELD 280 |
| City: | HEIDELBERG |
| State/Country: | GERMANY |
| Postal Code: | 69120 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Patent Number: | 10179123 |
| CORRESPONDENCE DATA | |
| Fax Number: | (650)494-0792 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 6508135993 |
| Email: | mchacon@mofa.com |
| Correspondent Name: | DAVID KEMPE |
| Address Line 1: | MORRISON & FOERSTER LLP - PA |
| Address Line 2: | 755 PAGE MILL ROAD |
| Address Line 4: | PALO ALTO, CALIFORNIA 94304-1018 |
| ATTORNEY DOCKET NUMBER: | 77705-20196.00 |
| NAME OF SUBMITTER: | DAVID KEMPE |
| SIGNATURE: | /David Kempe/ |
| DATE SIGNED: | 07/02/2020 |
| Total Attachments: 2 | |
| source=77705-20196.00 - Deutsches Krebsforschungszentrum Assignment SIGNED#page1.tif | |
| source=77705-20196.00 - Deutsches Krebsforschungszentrum Assignment SIGNED#page2.tif | |



ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: Bayer Pharma Aktiengesellschaft
Address: Müllerstr. 178, Berlin, Germany 13353
A juristic entity duly organized under and pursuant to the laws of: Germany

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the U.S. patent identified below:

U.S. Patent No.: 10,179,123 Issue Date: January 15, 2019

Title: 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS

This Assignment is to:

Assignee: Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts
Address: Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
A juristic entity duly organized under and pursuant to the laws of: Germany

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in confirmation of Assignor's prior agreement with Assignee, "Assignment Agreement by and between Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts and Bayer Pharma AG and Bayer AG" dated January 6, 2020, it is hereby confirmed,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.


sf-4165336

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:


Date: 4.2.2020

Signature: 

Name: Dr. Markus Aibers
Title: Senior Patent Counsel
Company: Bayer Pharma Aktiengesellschaft

ASSIGNEE:

Date: 17 MAR 2020

Signature: 

Name: Dr. Ruth Herzog
Title: ~~Senior Patent Counsel~~
Company: Deutsches Krebsforschungszentrum

Deputy Head of Innovation Management

sf-4165336